IE870784L - Compounds having a cognition adjuvant action - Google Patents
Compounds having a cognition adjuvant actionInfo
- Publication number
- IE870784L IE870784L IE870784A IE78487A IE870784L IE 870784 L IE870784 L IE 870784L IE 870784 A IE870784 A IE 870784A IE 78487 A IE78487 A IE 78487A IE 870784 L IE870784 L IE 870784L
- Authority
- IE
- Ireland
- Prior art keywords
- carboxylic acid
- carbethoxy
- alanyl
- phenylpropyl
- octane
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract description 65
- 239000002671 adjuvant Substances 0.000 title 1
- 230000019771 cognition Effects 0.000 title 1
- 239000005541 ACE inhibitor Substances 0.000 claims abstract description 11
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 230000001777 nootropic effect Effects 0.000 claims abstract description 6
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 125000004122 cyclic group Chemical group 0.000 claims description 66
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims description 26
- 125000004432 carbon atom Chemical group C* 0.000 claims description 25
- 229910052739 hydrogen Inorganic materials 0.000 claims description 25
- 239000001257 hydrogen Substances 0.000 claims description 20
- 229910052717 sulfur Inorganic materials 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 10
- DIOQZVSQGTUSAI-UHFFFAOYSA-N decane Chemical compound CCCCCCCCCC DIOQZVSQGTUSAI-UHFFFAOYSA-N 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000003003 spiro group Chemical group 0.000 claims description 5
- ADKDJHASTPQGEO-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[b]pyrrole Chemical compound C1CNC2CCCC21 ADKDJHASTPQGEO-UHFFFAOYSA-N 0.000 claims description 2
- UZHVXJZEHGSWQV-UHFFFAOYSA-N 1,2,3,3a,4,5,6,6a-octahydrocyclopenta[c]pyrrole Chemical compound C1NCC2CCCC21 UZHVXJZEHGSWQV-UHFFFAOYSA-N 0.000 claims description 2
- SBUWIPJHZAJVSM-UHFFFAOYSA-N 1,2,3,3a,4,5,6,7,8,8a-decahydrocyclohepta[b]pyrrole Chemical compound C1CCCCC2NCCC21 SBUWIPJHZAJVSM-UHFFFAOYSA-N 0.000 claims description 2
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 claims description 2
- ODSNARDHJFFSRH-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-isoindole Chemical compound C1CCCC2CNCC21 ODSNARDHJFFSRH-UHFFFAOYSA-N 0.000 claims description 2
- WSSDGZWSPMAECX-UHFFFAOYSA-N 2-azabicyclo[3.1.0]hexane Chemical compound C1CNC2CC21 WSSDGZWSPMAECX-UHFFFAOYSA-N 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- VXFJYXUZANRPDJ-MQBSTWLZSA-N (2s,3as,7as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-2,3,3a,4,5,6,7,7a-octahydroindole-2-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-MQBSTWLZSA-N 0.000 claims 1
- LALGNVUJKVMZMO-OCVXTVMPSA-N (3s,4as,8as)-2-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,4,4a,5,6,7,8,8a-octahydro-1h-isoquinoline-3-carboxylic acid Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCCC[C@@H]2C1)C(O)=O)CC1=CC=CC=C1 LALGNVUJKVMZMO-OCVXTVMPSA-N 0.000 claims 1
- NENLYAQPNATJSU-UHFFFAOYSA-N 1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline Chemical compound C1NCCC2CCCCC21 NENLYAQPNATJSU-UHFFFAOYSA-N 0.000 claims 1
- PDELQDSYLBLPQO-UHFFFAOYSA-N 2,3,3a,4,5,6,7,7a-octahydro-1h-indole Chemical compound C1CCCC2NCCC21 PDELQDSYLBLPQO-UHFFFAOYSA-N 0.000 claims 1
- NINJAJLCZUYDGV-UHFFFAOYSA-N 2-azaspiro[4.4]nonane Chemical compound C1CCCC21CNCC2 NINJAJLCZUYDGV-UHFFFAOYSA-N 0.000 claims 1
- SFCOKGCNIPSUQF-UHFFFAOYSA-N 2-azaspiro[4.5]decane Chemical compound C1NCCC21CCCCC2 SFCOKGCNIPSUQF-UHFFFAOYSA-N 0.000 claims 1
- GPRLTFBKWDERLU-UHFFFAOYSA-N bicyclo[2.2.2]octane Chemical compound C1CC2CCC1CC2 GPRLTFBKWDERLU-UHFFFAOYSA-N 0.000 claims 1
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 claims 1
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 10
- 238000011321 prophylaxis Methods 0.000 abstract description 8
- 230000001149 cognitive effect Effects 0.000 abstract 1
- 230000007257 malfunction Effects 0.000 abstract 1
- 239000000243 solution Substances 0.000 description 55
- -1 aliphatic radical Chemical class 0.000 description 49
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 42
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 17
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 238000000034 method Methods 0.000 description 15
- 239000002904 solvent Substances 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 150000003254 radicals Chemical class 0.000 description 14
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 235000019441 ethanol Nutrition 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- 239000002253 acid Substances 0.000 description 11
- 229960004756 ethanol Drugs 0.000 description 11
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 11
- 239000000203 mixture Substances 0.000 description 11
- 239000003826 tablet Substances 0.000 description 11
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 9
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 125000003118 aryl group Chemical group 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 8
- 150000002431 hydrogen Chemical class 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000002585 base Substances 0.000 description 7
- 208000010877 cognitive disease Diseases 0.000 description 7
- 238000002844 melting Methods 0.000 description 7
- 230000008018 melting Effects 0.000 description 7
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000001816 cooling Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 125000006239 protecting group Chemical group 0.000 description 6
- 229920006395 saturated elastomer Polymers 0.000 description 6
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 238000004440 column chromatography Methods 0.000 description 5
- 150000002148 esters Chemical class 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 125000001931 aliphatic group Chemical group 0.000 description 4
- 125000003342 alkenyl group Chemical group 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 239000012043 crude product Substances 0.000 description 4
- 239000008187 granular material Substances 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 239000003960 organic solvent Substances 0.000 description 4
- 239000011541 reaction mixture Substances 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- WJKHJLXJJJATHN-UHFFFAOYSA-N triflic anhydride Chemical compound FC(F)(F)S(=O)(=O)OS(=O)(=O)C(F)(F)F WJKHJLXJJJATHN-UHFFFAOYSA-N 0.000 description 4
- 208000000044 Amnesia Diseases 0.000 description 3
- 208000031091 Amnestic disease Diseases 0.000 description 3
- 229920002261 Corn starch Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 3
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 230000006986 amnesia Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 210000004781 brain capillary Anatomy 0.000 description 3
- 239000008120 corn starch Substances 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- 238000007327 hydrogenolysis reaction Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000000543 intermediate Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 150000002762 monocarboxylic acid derivatives Chemical class 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- NVXFXLSOGLFXKQ-JMSVASOKSA-N (2s)-1-[(2r,4r)-5-ethoxy-2,4-dimethyl-5-oxopentanoyl]-2,3-dihydroindole-2-carboxylic acid Chemical compound C1=CC=C2N(C(=O)[C@H](C)C[C@@H](C)C(=O)OCC)[C@H](C(O)=O)CC2=C1 NVXFXLSOGLFXKQ-JMSVASOKSA-N 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 2
- 125000003762 3,4-dimethoxyphenyl group Chemical group [H]C1=C([H])C(OC([H])([H])[H])=C(OC([H])([H])[H])C([H])=C1* 0.000 description 2
- XVMSFILGAMDHEY-UHFFFAOYSA-N 6-(4-aminophenyl)sulfonylpyridin-3-amine Chemical compound C1=CC(N)=CC=C1S(=O)(=O)C1=CC=C(N)C=N1 XVMSFILGAMDHEY-UHFFFAOYSA-N 0.000 description 2
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N Magnesium oxide Chemical compound [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 2
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- ITLHXEGAYQFOHJ-UHFFFAOYSA-N [diazo(phenyl)methyl]benzene Chemical compound C=1C=CC=CC=1C(=[N+]=[N-])C1=CC=CC=C1 ITLHXEGAYQFOHJ-UHFFFAOYSA-N 0.000 description 2
- 125000001980 alanyl group Chemical group 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 125000004103 aminoalkyl group Chemical group 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 150000001721 carbon Chemical group 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229910000510 noble metal Inorganic materials 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- PAQZWJGSJMLPMG-UHFFFAOYSA-N propylphosphonic anhydride Substances CCCP1(=O)OP(=O)(CCC)OP(=O)(CCC)O1 PAQZWJGSJMLPMG-UHFFFAOYSA-N 0.000 description 2
- HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 2
- 229960003401 ramipril Drugs 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000008215 water for injection Substances 0.000 description 2
- DYWSVUBJGFTOQC-UHFFFAOYSA-N xi-2-Ethylheptanoic acid Chemical compound CCCCCC(CC)C(O)=O DYWSVUBJGFTOQC-UHFFFAOYSA-N 0.000 description 2
- DTGKSKDOIYIVQL-WEDXCCLWSA-N (+)-borneol Chemical group C1C[C@@]2(C)[C@@H](O)C[C@@H]1C2(C)C DTGKSKDOIYIVQL-WEDXCCLWSA-N 0.000 description 1
- GHPYJLCQYMAXGG-WCCKRBBISA-N (2R)-2-amino-3-(2-boronoethylsulfanyl)propanoic acid hydrochloride Chemical compound Cl.N[C@@H](CSCCB(O)O)C(O)=O GHPYJLCQYMAXGG-WCCKRBBISA-N 0.000 description 1
- JNJCEALGCZSIGB-SECBINFHSA-N (2r)-2-hydroxy-4-phenylbutanoic acid Chemical compound OC(=O)[C@H](O)CCC1=CC=CC=C1 JNJCEALGCZSIGB-SECBINFHSA-N 0.000 description 1
- UTJXXYSZZZSYKY-ZSCHJXSPSA-N (2s)-2-amino-4-methylpentanoic acid;4-methylbenzenesulfonic acid Chemical compound CC(C)C[C@H](N)C(O)=O.CC1=CC=C(S(O)(=O)=O)C=C1 UTJXXYSZZZSYKY-ZSCHJXSPSA-N 0.000 description 1
- ILYVXUGGBVATGA-DKWTVANSSA-N (2s)-2-aminopropanoic acid;hydrochloride Chemical compound Cl.C[C@H](N)C(O)=O ILYVXUGGBVATGA-DKWTVANSSA-N 0.000 description 1
- CQYBNXGHMBNGCG-FXQIFTODSA-N (2s,3as,7as)-2,3,3a,4,5,6,7,7a-octahydro-1h-indol-1-ium-2-carboxylate Chemical compound C1CCC[C@@H]2[NH2+][C@H](C(=O)[O-])C[C@@H]21 CQYBNXGHMBNGCG-FXQIFTODSA-N 0.000 description 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 description 1
- JQBIKTMQCYTCII-UHFFFAOYSA-N 1,2,3,3a,4,6a-hexahydrocyclopenta[b]pyrrole Chemical compound C1C=CC2NCCC21 JQBIKTMQCYTCII-UHFFFAOYSA-N 0.000 description 1
- BWKMGYQJPOAASG-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid Chemical compound C1=CC=C2CNC(C(=O)O)CC2=C1 BWKMGYQJPOAASG-UHFFFAOYSA-N 0.000 description 1
- ADFXKUOMJKEIND-UHFFFAOYSA-N 1,3-dicyclohexylurea Chemical compound C1CCCCC1NC(=O)NC1CCCCC1 ADFXKUOMJKEIND-UHFFFAOYSA-N 0.000 description 1
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- MFOUWLGLIHXCOZ-UHFFFAOYSA-N 2,3,3a,4,5,7a-hexahydro-1h-indole Chemical compound C1CC=CC2NCCC21 MFOUWLGLIHXCOZ-UHFFFAOYSA-N 0.000 description 1
- XRKXJJYSKUIIEN-UHFFFAOYSA-N 2-[cyclopentyl-[3-(2,2-dimethylpropanoylsulfanyl)-2-methylpropanoyl]amino]acetic acid Chemical compound CC(C)(C)C(=O)SCC(C)C(=O)N(CC(O)=O)C1CCCC1 XRKXJJYSKUIIEN-UHFFFAOYSA-N 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004042 4-aminobutyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])N([H])[H] 0.000 description 1
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 description 1
- 125000004217 4-methoxybenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1OC([H])([H])[H])C([H])([H])* 0.000 description 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- FHHHOYXPRDYHEZ-COXVUDFISA-N Alacepril Chemical compound CC(=O)SC[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 FHHHOYXPRDYHEZ-COXVUDFISA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- HWNLPUUJBHRNRT-UHFFFAOYSA-N C1=C2N(CC(N1)=O)C=CC2=O Chemical compound C1=C2N(CC(N1)=O)C=CC2=O HWNLPUUJBHRNRT-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FDJCVHVKXFIEPJ-JCNFZFLDSA-N Delapril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N(CC(O)=O)C1CC2=CC=CC=C2C1)CC1=CC=CC=C1 FDJCVHVKXFIEPJ-JCNFZFLDSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108010007859 Lisinopril Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- UWWDHYUMIORJTA-HSQYWUDLSA-N Moexipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC(OC)=C(OC)C=C2C1)C(O)=O)CC1=CC=CC=C1 UWWDHYUMIORJTA-HSQYWUDLSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010039966 Senile dementia Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- VXFJYXUZANRPDJ-WTNASJBWSA-N Trandopril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@H]2CCCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 VXFJYXUZANRPDJ-WTNASJBWSA-N 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 238000007171 acid catalysis Methods 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000005041 acyloxyalkyl group Chemical group 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 229950007884 alacepril Drugs 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000002723 alicyclic group Chemical group 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 description 1
- 125000005205 alkoxycarbonyloxyalkyl group Chemical group 0.000 description 1
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 description 1
- 125000006350 alkyl thio alkyl group Chemical group 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 125000003435 aroyl group Chemical group 0.000 description 1
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 description 1
- 125000005110 aryl thio group Chemical group 0.000 description 1
- 125000005164 aryl thioalkyl group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- VPSRQEHTHIMDQM-FKLPMGAJSA-N benazepril hydrochloride Chemical compound Cl.C([C@@H](C(=O)OCC)N[C@@H]1C(N(CC(O)=O)C2=CC=CC=C2CC1)=O)CC1=CC=CC=C1 VPSRQEHTHIMDQM-FKLPMGAJSA-N 0.000 description 1
- ODXRLCORPKTWCY-OAQYLSRUSA-N benzhydryl (2r)-2-hydroxy-4-phenylbutanoate Chemical compound C([C@@H](O)C(=O)OC(C=1C=CC=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 ODXRLCORPKTWCY-OAQYLSRUSA-N 0.000 description 1
- AQGYIIJBBCFLEP-OAQYLSRUSA-N benzhydryl (2r)-4-phenyl-2-(trifluoromethylsulfonyloxy)butanoate Chemical compound C([C@@H](OS(=O)(=O)C(F)(F)F)C(=O)OC(C=1C=CC=CC=1)C=1C=CC=CC=1)CC1=CC=CC=C1 AQGYIIJBBCFLEP-OAQYLSRUSA-N 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 125000001300 boranyl group Chemical group [H]B([H])[*] 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000005242 carbamoyl alkyl group Chemical group 0.000 description 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000004181 carboxyalkyl group Chemical group 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003610 charcoal Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- HHHKFGXWKKUNCY-FHWLQOOXSA-N cilazapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H]1C(N2[C@@H](CCCN2CCC1)C(O)=O)=O)CC1=CC=CC=C1 HHHKFGXWKKUNCY-FHWLQOOXSA-N 0.000 description 1
- 229960005025 cilazapril Drugs 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000013256 coordination polymer Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 1
- 150000001991 dicarboxylic acids Chemical class 0.000 description 1
- RDXABLXNTVBVML-UHFFFAOYSA-N diethoxyphosphanyl diethyl phosphite Chemical compound CCOP(OCC)OP(OCC)OCC RDXABLXNTVBVML-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- KIVIOCIZZDVFRY-UHFFFAOYSA-N dodecyl 2-oxo-4-phenylbutanoate Chemical compound CCCCCCCCCCCCOC(=O)C(=O)CCC1=CC=CC=C1 KIVIOCIZZDVFRY-UHFFFAOYSA-N 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- MQGTZMCASHTGBJ-UHFFFAOYSA-N ethyl 2-hydroxypentanoate Chemical compound CCCC(O)C(=O)OCC MQGTZMCASHTGBJ-UHFFFAOYSA-N 0.000 description 1
- IIEWJVIFRVWJOD-UHFFFAOYSA-N ethyl cyclohexane Natural products CCC1CCCCC1 IIEWJVIFRVWJOD-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000003818 flash chromatography Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229940076701 hydro 35 Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 229950009810 indolapril Drugs 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 1
- 229960002394 lisinopril Drugs 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 150000002668 lysine derivatives Chemical class 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000000395 magnesium oxide Substances 0.000 description 1
- 150000002688 maleic acid derivatives Chemical class 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 150000002763 monocarboxylic acids Chemical class 0.000 description 1
- 239000012452 mother liquor Substances 0.000 description 1
- BSIZUMJRKYHEBR-QGZVFWFLSA-N n-hydroxy-2(r)-[[(4-methoxyphenyl)sulfonyl](3-picolyl)amino]-3-methylbutanamide hydrochloride Chemical compound C1=CC(OC)=CC=C1S(=O)(=O)N([C@H](C(C)C)C(=O)NO)CC1=CC=CN=C1 BSIZUMJRKYHEBR-QGZVFWFLSA-N 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- LYGJENNIWJXYER-UHFFFAOYSA-N nitromethane Chemical compound C[N+]([O-])=O LYGJENNIWJXYER-UHFFFAOYSA-N 0.000 description 1
- ZCYXXKJEDCHMGH-UHFFFAOYSA-N nonane Chemical compound CCCC[CH]CCCC ZCYXXKJEDCHMGH-UHFFFAOYSA-N 0.000 description 1
- 239000002664 nootropic agent Substances 0.000 description 1
- BKIMMITUMNQMOS-UHFFFAOYSA-N normal nonane Natural products CCCCCCCCC BKIMMITUMNQMOS-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 229950008492 pentopril Drugs 0.000 description 1
- 238000005897 peptide coupling reaction Methods 0.000 description 1
- IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 description 1
- 229960002582 perindopril Drugs 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229960004526 piracetam Drugs 0.000 description 1
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 235000015497 potassium bicarbonate Nutrition 0.000 description 1
- 229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
- 239000011736 potassium bicarbonate Substances 0.000 description 1
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- WRHZVMBBRYBTKZ-UHFFFAOYSA-N pyrrole-2-carboxylic acid Chemical compound OC(=O)C1=CC=CN1 WRHZVMBBRYBTKZ-UHFFFAOYSA-N 0.000 description 1
- JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- PKEIECQHMLJGQB-UHFFFAOYSA-N spiro[bicyclo[2.2.2]octane-2,3'-pyrrolidine]-5-carboxylic acid Chemical compound OC(=O)C1CC2CCC1CC21CCNC1 PKEIECQHMLJGQB-UHFFFAOYSA-N 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000001578 tight junction Anatomy 0.000 description 1
- 229910052723 transition metal Inorganic materials 0.000 description 1
- 150000003624 transition metals Chemical class 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/022—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
- C07K5/0222—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Abstract
The invention relates to novel compounds having a nootropic activity, the use of ACE inhibitors as medicaments having nootropic activity, agents containing them, and their use in the treatment and prophylaxis of cognitive malfunctions.
Description
O Z H J J - 1 - The invention relates to the use of angiotensin converting enzyme inhibitors (ACE inhibitors) or their physiologically tolerated salts as medicaments having a nootropic action (improving cognitive function) and to 5 the use thereof in the preparation of corresponding pharmaceutical formulations. ACE inhibitors with various heterocyclic structures which can be used to reduce blood pressure are known from EP-A-050800 and EP-A-116276.
Examples of suitable compounds for this novel use are 10 those of the formula II r3ooc - oh - h - c - ra - n - p - (chz)n-r Cxi) n r 0 r c00r2 in which n is 1 or 2, R denotes hydrogen, an aliphatic radical having 1-21 carbon atoms, 15 an aromatic radical having 6-12 carbon atoms, R1 denotes hydrogen, an aliphatic radical having 1-21 carbon atoms, or if not already covered by the above definitions, the side-chain, protected where necessary, of a 20 naturally occurring a-amino acid, R3 and R3 are identical or different and denote hydrogen, an aliphatic radical having 1-21 carbon atoms, an alicyclic radical having 3-20 carbon atoms, an aromatic radical having 6-12 carbon atoms, 25 an araliphatic radical having 7-32 carbon atoms, and R* and R5 form, together with the atoms carrying them, a mono-, bi- or tricyclic heterocyclic ring system having 3 to 15 ring carbon atoms.
An aliphatic radical is understood to be an aliphatic 30 acyclic radical, i.e. a radical with an open, straight or branched carbon chain such as, for example, alkyl, alkenyl, alkynyl and corresponding multiply unsaturated - 2 - radicals. It is preferably unsubstituted or, as described below, for example, for carboxyl, carbamoyl, aminoalkyl, alkanoylaminoalkyl, alkoxycarbonylaminoalkyl, arylalkoxycarbonylaminoalkyl, arylalkylaminoalkyl, alkyl-5 aminoalkyl, dialkylaminoalkyl, alkylthioalkyl, arylthio-alkyl, carboxyalkyl, carbamoylalkyl, alkoxycarbonylalkyl, alkanoyloxyalkyl, alkoxycarbonyloxyalkyl, aroyloxyalkyl or aryloxycarbonyloxyalkyl, monosubstituted.
An alicyclic radical, and the corresponding optionally substituted alicyclic-aliphatic radical which is linked via an open carbon chain, is a preferably mono- to pentacyclic, isocyclic, nonaromatic radical which has single bonds or asymmetrically distributed double bonds and can also be branched (i.e. carry open-chain aliphatic side-chains) and is linked via a ring carbon atom or a side-chain carbon atom. It is preferably unsubstituted. When several rings are components of a radical of this type, they are fused, spiro-linked or isolated. Examples of radicals of this type are cycloalkyl, cycloalkenyl, cycloalkylalkyl, bicycloalkyl, tricycloalkyl and radicals derived from mono-, bi- or oligocyclic terpenes such as menthyl, isomenthyl, boranyl, bornyl, caranyl, epibomyl, epiisobornyl, isoborayl, menthanyl, neomenthyl, neoiso-menthyl, pinanyl and thujanyl; they are preferably unsubstituted (according to the present definition, aliphatic side-chains are not substituents).
An aromatic radical is preferably aryl such as phenyl, biphenylyl or naphthyl, which is optionally mono-, di- or trisubstituted as indicated below for aryl. Radicals 30 derived from aryl, such as aralkyl, aryloxy, arylthio or aroyl, preferably benzoyl, can be substituted as for aryl.
An araliphatic radical is understood to be, in particular, aralkyl radicals such as arylalkyl, diarylalkyl, 35 indanyl or fluorenyl, in which aryl is as defined above and which can be substituted in the maimer indicated 10 15 20 25 - 3 - there.
R4 and R5 can form, with the atoms carrying them, a mono-, bl- or tricyclic heterocyclic ring system which has 3 to 15 ring carbon atoms and preferably has up to 2 sulfur 5 atoms and up to 2 nitrogen atoms In the ring, In particular up to 1 sulfur atom.
Particularly suitable ring systems of these types are those of the following group: Pyrrolidine (0); tetrahydrolsoqulnollne (A) ; decahydro-10 Isoqulnollne (B) ; octahydrolndole (C); Indollne (Q) ; octahydrocyclopenta[b]pyrrole (D); 2-azasplro[4.5]decane (E) ; 2-azasplro[4.4]nonane (F) ; spiro[(bicyclo[2.2.1]-heptane)-2,3'-pyrrolidine] (G); spiro[(bicyclo[2.2.2]-octane)-2,3'-pyrrolidine] (H); 2-azatricyclo [4.3.0.Is'9] -15 decane (I); decahydrocyclohepta[b]pyrrole (J); octahydro-isoindole (K) ; octahydrocyclopenta[c]pyrrole (L) ; 2, 3, 3a,4,5,7a-hexahydroindole (M) ; 2-azabicyclo[3.1.0]-hexane (N) ; 1,2,3,3a,4,6a-hexahydrocyclopenta[b]pyrrole (P) , all of which can optionally be substituted. 20 Pyrrolidine (O) and thiazolidine (R); can be monosubstituted by, for example, (Cs-C12)-aryl, (phenyl, 2-hydroxy-phenyl etc.), (C6-C13)-arylmercapto (such as phenyl-mercapto) or (C3-C7)-cycloalkyl (such as cyclohexyl). Tetrahydroisoquinoline (A) can carry, for example, in the 25 aryl moiety, up to 2 (C^-Cj)-alkoxy radicals, preferably methoxy radicals. A corresponding statement applies to the other ring systems. However, the unsubstituted systems are preferred.
With compounds of the formula II which have several 30 chiral atoms all possible diastereomers, as racemates or enantiomers, or mixtures of various diastereomers are suitable.
The suitable heterocyclic ring systems have the following structural formulae. - 4 - CG^'q^ COOR" 03w0v COOR U C3-CP°R3 e k T ^»'^~C0Wl' ===*> Cp-===«3 QCy k £ S cd-"°r^cdor3 8- COOR" 8wQ> M H coor3 CO CQ" coor- \ coor* - 5 - A preferred embodiment comprises use of compounds of the formula I, preferably those of the formula II/ in which n is 1 or 2, R denotes hydrogen, 5 alkyl having 1-8 carbon atoms, alkenyl having 2-6 carbon atoms, aryl which has 6-12 carbon atoms, R1 denotes hydrogen, alkyl having 1-6 carbon atoms, 10 alkenyl having 2-6 carbon atoms, alkynyl having 2-6 carbon atoms, or the optionally protected side-chain of a naturally occurring a-amino acid, R1-CH(NHa) -COOH, 15 R2 and R3 are identical or different and denote hydrogen, alkyl having 1-6 carbon atoms, alkenyl having 2-6 carbon atoms, aryl having 6-12 carbon atoms, (Cs-C12) -aryl- (C^C^) -alkyl, 20 (Cj-Cj) -cycloalkyl or and R4 and R5 have the abovementioned meaning, particularly such compounds in which n is 1 or 2, 25 R denotes (Cx-C6) -alkyl, (C2-C6) -alkenyl, (C6-C12)-aryl, in particular methyl, ethyl or phenyl R1 denotes hydrogen or (C^-Cg) -alkyl, (C2-C6)-alkenyl, or a side-chain of a naturally occurring, optionally protected a-amino acid, but in particular hydrogen, 30 (Ci-Cj)-alkyl, (C2 or C3)-alkenyl, the optionally protected side-chain of lysine, benzyl, 4-methoxy-benzyl, 4-ethoxybenzyl, phenethyl, 4-aminobutyl or benzoylmethyl, R2 and R3 denote identical or different radicals hydrogen, 35 (Cj-C,)-alkyl, (C2-Cs)-alkenyl or (C6-Cl2)-aryl- fCj-C,)-alkyl, but in particular hydrogen, (Cj-C^ -alkyl or benzyl, and R4 and R5 have the abovementioned meaning. - 6 - If R1 represents a side-chain of a protected naturally occurring a-amino acid/ such as, for example, protected Ser, Thr, Asp, Asn, Glu, Gin, Arg, Lys, Hyl, Cys, Orn, Cit, Tyr, Trp or His, preferred protective groups are the 5 groups customary in peptide chemistry (cf. Houben-Weyl, vol. XV/1 and XV/2) . In the case where R1 denotes the protected side-chain of lysine, the known amino protective groups are preferred, but in particular Z, Boc or (Cx-C6)-alkanoyl. Suitable and preferred O-protective 10 groups for tyrosine are (Cj-C6) -alkyl, in particular methyl or ethyl.
It is possible and particularly advantageous to use the following compounds according to the invention: 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -S-l,2,3,4-15 tetrahydroisoquinoline-3-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -S-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl)-S-lysyl]-S-l,2,3,4-tetrahydroisoguinoline-3-carboxylic acid 20 2- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-S-tyrosyl]-S-l,2,3,4-tetrahydroisoquinoline-3-carboxylic acid 2-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-(3S)-decahydroisoquinoline-3-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] - (2S, 3aS, 25 7aS)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1-[N-(l-S-carbethoxy-3-phenylpropyl)-S-lysyl]-(2S,3aS, 7aS)-octahydroindole-2-carboxylic acid 30 1- [N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-(2S, 3aS,7aS)-octahydroindole-2-carboxylic acid 1-[N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-(2S, 3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) -O-methyl-S-tyrosyl] -35 (2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-S-tyrosyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1 - [N-(l-S-carbethoxy-3-(3,4-dixaethylphenylpropyl)-S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N-[l-S-carbethoxy-3-(4-fluoropheayl)-propyl] -S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N-[l-S-carbethoxy-3-(4-methoxyphenyl)-propyl]-S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N- [l-S-carbethoxy-3- (3,4-dimethoxyphenyl) -propyl] -S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1-[N-(l-S-carbethoxy-3-cyclopentylpropyl)-S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] - (2S,3aR, 7aS)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] - (2S, 3aR,7aS)-octahydroindole-carboxylic acid 1-[N-(l-S-carbethoxy-3-phenylpropyl)-S-lysyl]-(2S,3aR, 7aS)-octahydroindole-2-carboxylic acid 1-[N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-(2S# 3aR,7aS)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-S-tyrosyl]- (2S,3aS,7aR)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] - (2S,3aR, 7aR)-octahydroindole-2-carboxylic acid 1-[N-(l-S-carbethoxy-3-phenylpropyl)-S-lysyl]-(2S,3aR, 7aS)-octahydroindole-2-carboxylic acid 1- [N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-(2S,3aR,7aR)-octahydroindole-2-Carboxylic acid 1- [N- (l-S-carbethoxy-3-cyclohexylpropyl)-O-ethyl-S-tyrosyl] -(2S,3aR,7aR)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] - (2S,3aS, 7aR)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-S-tyrosyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3,4-dimethylphenylpropyl) -S-alanyl] -(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N-[l-S-carbethoxy-3- (4-fluorophenyl)-propyl] -S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N- [l-S-carbethoxy-3-(4-methoxyphenyl)-propyl]-S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N- [l-S-carbethoxy-3- (3,4-dimethoxyphenyl) -propyl] -S- - 8 - alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 1- [N-(l-S-carbethoxy-3-cyclopentylpropyl)-S-alanyl]-(2S,3aS,7aS)-octahydroindole-2-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -cis-endo-5 2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-lysyl] -cis-endo-2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -cis-endo-2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 10 2- [N- (l-S-carboxy-3-cyclohexylpropyl) -S-alanyl] -cis-endo-2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 2- [N- (1-S-carbethoxy-butyl) -S-alanyl] -cis-endo-2-aza-bicyclo [3.3.0] octane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3- (3,4-dimethoxyphenylpropyl) -S-15 alanyl] -cis-endo-2-azabicyclo[3.3.0] octane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclopentylpropyl)-S-alanyl]-cis-endo -azabicyclo-[3.3.0]octane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -O-methyl-S-tyrosyl] -20 cis-endo-2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-S-tyrosyl]-cis-endo-2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3 - (4-fluorophenylpropyl) -S-alanyl] -cis-endo-2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 25 2- [N- (l-S-carbethoxy-3- (4-methoxyphenylpropyl) -S-alanyl] -cis-endo-2-azabicyclo[3.3.0]octane-3-S-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) - S-lysyl] - (2S, 3aR 6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1-[N-(l-S-carbethoxy-3-cyclohexylpropyl)-lysyl]-(2S, 30 3aR,6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl]-O-ethyl-S-tyrosyl]-(2S, 3aR, 6aS) -octahydrocyclopenta [b]pyrrole-2-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -2- (2S,3aR, 35 6aS)-octahydrocyclopenta[b]pyrrole-2-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -2-aza-spiro-[4.5]decane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-2-tyrosyl]-2-azaspiro-[4.5]decane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-lysyl] -2-azaspiro-[4.5]decane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -2-aza-spiro[4.5]decane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-2-aza-spiro[4.5]decane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -2-aza-spiro[4.4]nonane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-S-tyrosyl]-2-azaspiro[4.4]nonane-3-S-carboxylic acid 2 -[N-(l-S-carbethoxy-3-phenylpropyl)-S-lysyl]-2-azaspiro [4.4]nonane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -2-aza-spiro[4.4]nonane-3-S-carboxylic acid 2-[N-(l-S-carbethoxy-3-cyclopentylpropyl)-S-alanyl]-2-azaspiro[4.4]nonane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclopentylpropyl) -S-lysyl] -2-aza-spiro[4.4]nonane-3-S-carboxylic acid 1' - [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -spiro [bicyclo [2.2.1]heptane-2,3'-pyrrolidine] -5'-S-carboxylic acid 1' - [N- (l-S-carbethoxy-3-phenylpropyl) -O-ethyl-S-tyrosyl] -spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]- 5'-S-carboxylic acid 1' - [N-(l-S-carbethoxy-3-phenylpropyl)-S-lysyl]-spiro[bicyclo [2.2.1]heptane-2,3' -pyrrolidine]-5'-S-carboxylic acid 1' - [N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine] 5' - S-carboxylic acid 1' - [N- (l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-spiro[bicyclo[2.2.1]heptane-2,3'-pyrrolidine]-5'-S-carboxylic acid 1'-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-spiro-[bicyclo [2.2.2] octane-2,3' -pyrrolidine] -5' -S-carboxylic acid 1'-[N-(l-S-carbethoxy-3-phenylpropyl)-0-ethyltyrosyl]-spiro-[bicyclo[2.2.2]octane-2,3'-pyrrolidine]- 5'-S-carboxylic acid - 10 - 1' - [N- (l-S-carbethoxy-3-phenylpropyl) -S-lysyl] -spiro [bicyclo [2.2.2]octane-2,3'-pyrrolidine]-5'-S-carboxylic acid 1'-[N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-spiro[bicyclo[2.2.2]octane-2,3'-pyrrolidine] -5' - S-5 carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -2-azatri-cyclo [4.3.0. I6'9] decane-3 -S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -O-ethyl-S-tyrosyl] -2-azatricyclo [4.3.0.I6,9] decane-3-S-carboxylic acid 10 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-lysyl] -2-azatri-cyclo [4.3.0.16'9] decane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -2-azatricyclo[4.3.0. I6,9]decane-3-S-carboxylic acid 2-[N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-2-15 azatricyclo [4.3.0. Is'9] decane-3-S-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] - decahydro-cyclohepta[b]pyrrole-2-S-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl)-O-ethyl-S-tyrosyl]-decahydrocyclohepta[b]pyrrole-2-S-carboxylic acid 20 1- [N- (l-S-carbethoxy-3-phenylpropyl) -S-lysyl] -decahydrocyclohepta [b]pyrrole-2-S-carboxylic acid 1- [N- (l-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-decahydrocyclohepta[b]pyrrole-2-S-carboxylic acid 1- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-lysyl] -deca-25 hydrocyclohepta[b]pyrrole-2-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -trans-octahydroisoindole-1-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-cis-octahydroisoindole-1-S-carboxylic acid 30 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -trans-octahydroisoindole-l-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -cis-octahydroisoindole-l-S-carboxylic acid 2- [N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-cis-35 octahydrocyclopenta[c]pyrrole-l-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -cis-octahydrocyclopenta[c]pyrrole-l-S-carboxylic acid benzyl ester 2-[N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-cis- - 11 - octahydrocyclopenta[c]pyrrole-l-S-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-2,3,3a,4 5,7a-hexahydroindole-cis-endo-2-S-carboxylic acid 1- [N- (l-S-carbethoxy-3-phenylpropyl) - S-lysyl] -2,3,3a,4 5 5,7a-hexahydroindole-cis-endo-2-S-carboxylic acid 2-[N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-lysyl]-2 azabicyclo [3.1.0] hexane-3- S-carboxylic acid 2- [N- (l-S-carboxy-3-phenylpropyl) -S-lysyl] -2-azabicyclo [3.1.0]hexane-cis-endo-3-S-carboxylic acid 10 2- [N-(l-S-carbethoxy-3-cyclopentylpropyl)-S-alanyl]-2 azabicyclo [3.1.0] hexane-3-carboxylic acid 2- [N- (l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-cis-endo 2-azabicyclo[3.1.0]hexane-3-S-carboxylic acid 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl) -S-alanyl] -cis 15 endo-2-azabicyclo[3.1.0]hexane-3-S-carboxylic acid 1'-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl] (3' S, 5' S) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' carboxylic acid 1'- [N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl] 20 (3' R, 5' S) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' carboxylic acid 1'-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl] (3' S, 5'R) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' carboxylic acid 25 1'-[N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl] (3 'R, 5'R) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' carboxylic acid 1'- [N-(l-R-carbethoxy-3-phenylpropyl)-S-alanyl] (3' S, 5'R) -spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' 30 carboxylic acid 1'-[N- (1-R-carbethoxy- 3-phenylpropyl)-S-alanyl] (3' S, 5' S) - spiro-bicyclo [2.2.2] octane,2,3' -pyrrolidine-5' carboxylic acid 1'- [N- (l-R-carbethoxy-3-phenylpropyl)-S-alanyl] 35 (3'R,5'S) -spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' carboxylic acid 1'-[N-(l-R-carbethoxy-3-phenylpropyl)-S-alanyl] (3'R,5'R)-spiro-bicyclo[2.2.2]octane-2,3'-pyrrolidine - 12 - 5'-carboxylic acid 1'-[N-(l-S-carbethoxy-3-phenylpropyl)-R-alanyl]-(3' S , 5' S) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine- 5' -carboxylic acid 5 1'-[N-(l-S-carbethoxy-3-phenylpropyl)-R-alanyl]-(3' R, 5' S) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' -carboxylic acid 1' - [M-(l-S-carbethoxy-3-phenylpropyl)-R-alanyl]-(3' S, 5'R) -spiro-bicyclo[2.2.2] octane-2,3' -pyrrolidine-5' -10 carboxylic acid 1'-[N-(1-S-carbethoxy-3-phenylpropyl)-R-alanyl]-(3'R,5'R) -spiro-bicyclo[2.2.2]octane-2,3' -pyrrolidine-5' -carboxylic acid 1'-[N-(l-R-carbethoxy-3-phenylpropyl)-R-alanyl]-15 (3'S,5'S) -spiro-bicyclo[2.2.2]octane-2,3' -pyrrolidine-5' -carboxylic acid 1'- [N-(l-R-carbethoxy-3-phenylpropyl)-R-alanyl]-(3' R, 5' S) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine- 5' -carboxylic acid 20 1' - [N-(l-R-carbethoxy-3-phenylpropyl)-R-alanyl]-(3' S, 5'R) - spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' -carboxylic acid 1'-[N-(l-R-carbethoxy-3-phenylpropyl)-R-alanyl]-(3'R, 5'R) -spiro-bicyclo[2.2.2] octane-2,3' -pyrrolidine-5' -25 carboxylic acid These compounds can be prepared by, for example, the process described in German Patent Application P 33 33 455.2, in which the tert.-butyl or benzyl derivatives described in the application are converted in a known 30 manner, by acid or alkaline hydrolysis or by hydrogen -olysis catalyzed with noble metals, into the mono-car boxy lie acid derivatives. The N*-benzyloxycarbonyl protective group of the lysine derivatives is removed by hydrogenolysis catalyzed with noble metals. The compounds 35 listed above can readily be converted with physiologically tolerated acids or bases (in the case of mono- or dicarboxylic acids) into the corresponding salts (for example hydrochlorides, maleates, fumarates etc.), and be - 13 - 10 15 20 used as salts according to the invention.
The compounds of the formula II are inhibitors of angiotensin converting enzyme (ACE) or are intermediates in the preparation of such inhibitors, and they can also be used for controlling high blood pressure of a variety of etiologies. Some of the compounds of the formula II and processes for their preparation are disclosed in, for example, US Patent 4,129,571, US Patent 4,374,829, European Patent A-79522, European Patent A-79022, European Patent A-49658, European Patent A-51301, US Patent 4,454,292, US Patent 4,374,847, European Patent A-72352, US Patent 4,350,704, European Patent A-50800, European Patent A-46953, US Patent 4,344,949, European Patent A-84164, US Patent 4,470,972, European Patent A-65301 and European Patent A-52991. New compounds of the formula II are prepared in an analogous manner.
Orally effective ACE inhibitors (some of the active compounds already mentioned above) are also advantageous, such as, for example, ramipril, enalapril(f), pentopril(a), lisinopril(g), cilazapril(o), RHC 3659, CGS 13945, CGS 13928C(1), CGS 14824A(h), CI-906(j), alacepril, CI-925(k), CV 3317(m), indolapril(h), perindopril(i), and others. Orally effective ACE inhibitors are described in, for example, Brunner et al., J. Cardiovasc. Pharmacol. 7 (Suppl. I) id="p-1985" id="p-1985"
id="p-1985"
[1985] S2-S11. - 14 - h i C-CH-NH- r. — -t * 0 (CH2)4-KH2 &2h 2' CH-NH-CH' °" Oi. rn r H W CHg CO^ rrr x~UkA vf-nh-f o c*, cojcjhj V A. rn r H *3 c®2^2H5 (1) *'«h (j) x's 3,4 001,00 J>CH-NH-CH K-00 CH-NH-CH cHg co2c2hs (1) i. L ffl2=VS> chj-»jh 01, cdjcjhj I 0 m u CD_r H_ '£' CH2-C02H (n) O2H azVs ,£' oAf-"ra^ Wj coAHs (q) - 15 - The ACE inhibitors which are disclosed in European Patent A-79022 and are of the formula III COOH (S) (5) H - p - HH - CH - CH, - CH 0 CH. ioon r\ (in) in which R denotes hydrogen, methyl, ethyl or benzyl, are preferred, in particular the compound of the formula III in which R denotes ethyl (ramipril).
Also preferred are the ACE inhibitors which are disclosed in European Patent A-84164 and are of the formula IV B \^\* C00H H > - CH - HH - CH - CH2 - CH2 -/J 0 CH3 COOR* • in which 10 R4 denotes hydrogen, (Cx-C4) -alkyl or benzyl, in particular the compound of the formula IV in which R4 denotes ethyl.
Furthermore, preference is given to 1' -[N-(l-S-carboethoxy-3-phenylpropyl)-S-alanyl]-exo- or 15 endo-spirobicyclo[2.2.2]octane-2,3'-pyrrolidin-5'-ylcar-boxylic acid and isomers, and (S,S,S)-l-methyl-2-(1-carbethoxy-3-phenylpropyl) -2H-undecahydrocyclopenta[4.5] -pyrrolo[l,2-a]pyrazine-3,8-dione.
The invention also relates to new compounds of the 20 formula II - 16 - The capillary structure o£ the blood vessels in the brain differs from that in other regions of the body. The brain capillaries are surrounded by a layer of endothelial cells which are particularly closely linked together (by 5 tight junctions). In addition, brain capillaries have very many fewer of the pores through which, in other blood capillaries, low molecular weight substances can penetrate into or emerge from the surrounding tissue. In this way, in the brain capillaries the property of lipid 10 solubility has a very much greater importance for partition between blood and surrounding tissue than is the case for the remainder of the body.
Hence the preferred compounds of the formula II are those in which at least one of the radicals R, R1, R3 and R3 15 represents a lipophilic radical, such as a long-chain aliphatic, alicyclic-aliphatic, araliphatic or heteroar-aliphatic radical, a sufficiently large alicyclic radical, or an appropriately substituted alicyclic, aromatic or heteroaromatic radical, or contains a radical 20 of this type as a part-structure.
The invention also relates to a process for the preparation of a compound of the formula II, which comprises reacting together its fragments in a suitable solvent, where appropriate in the presence of a base and/or of a 25 coupling aid, reducing, where appropriate, unsaturated compounds which have formed as intermediates, such as Schiff's bases, eliminating protective groups which have been introduced temporarily to protect reactive groups, esterifying, where appropriate, compounds of the formula 30 II having one or more free carboxyl groups, and converting, where appropriate, the resulting compounds into - 17 - 10 15 their physiologically tolerated salts.
It is possible, for example, in the said manner to react compounds of the formula V with compounds of the formula The reaction of these compounds can be carried out, for example, in analogy to known peptide coupling methods in an organic solvent such as DMF, CHjClj or DMA in the presence of coupling aids such as carbodiimides (for example dicyclohexylcarbodiimide), diphenylphosphoryl azide, alkanephosphoric anhydrides, dialkylphosphinic anhydrides or N,N-succinimidyl carbonates, in a solvent such as CH3CN. Amino groups in compounds of the formula V can be activated with tetraethyl diphosphite. The compounds of the formula VI can be converted into active esters (for example with 1-hydroxybenzotriazole), mixed anhydrides (for example with chloroformic esters), azides or carbodiimide derivatives and thus activated (cf. Schroder, Lubke, The Peptides, volume 1, New York 1965, pages 76 -136) . The reaction is preferably carried out between -20°C and the boiling point of the reaction mixture.
It is likewise possible to react compounds of the formula VII with compounds of the formula VIII with the formation of compounds of the formula II VI. (v) (VI) (vii) (VIII) - 18 - in which either Y1 represents amino and Y3 represents a leaving group, or Y1 represents a leaving group and Y3 represents amino. Examples of suitable leaving groups are CI, Br, I, alkylsulfonyloxy or arylsulfonyloxy. 5 Alkylatlons of this type are expediently carried out in water or an organic solvent such as a lower aliphatic alcohol (such as ethanol), benzyl alcohol, acetonitrile, nitromethane or glycol ethers, at a temperature between -20°C and the boiling point of the reaction mixture, in 10 the presence of a base such as an alkali metal hydroxide or an organic amine.
Furthermore, it is possible to condense compounds of the formula IX with compounds of the formula X in which either Q1 represents amino + hydrogen and Q2 15 represents oxo, or Q1 represents oxo and Q3 represents amino + hydrogen. The condensation is expediently carried out in water or an organic solvent such as a lower aliphatic alcohol, at a temperature between -20°C and the boiling point of the reaction mixture, in the presence of 20 a reducing agent, such as NaBH,CN, compounds of the formula I being obtained directly. However, it is also possible to reduce Schiff's bases or enamines which are produced as intermediates, where appropriate after previous isolation, with the formation of compounds of 25 the formula II, for example by hydrogenation in the presence of a transition metal catalyst.
Finally, reaction of compounds of the formula IX (Q1 ■ H + NH2) with compounds of the formula XI, or their reaction with compounds of the formula XII and XIII, expedi-30 ently in the presence of a base such as sodium r300c-ch-n—c-c-«q1 «2- In the abovementioned formulae V - XIII, R - R5 and n are as defined in formula II. Protective groups temporarily introduced to protect reactive groups not involved in the 15 reaction are eliminated in a manner known per se after the reaction is complete (cf. Schroder, Lubke, loc. cit., pages 1-75 and 246 - 270; Greene, "Protective Groups in Organic Synthesis", New York 1981).
The new compounds of the formula I or II can also be 20 prepared, for example, using methods of esterification familiar to the expert (see, for example, Buchler, Pearson, Survey of Organic Syntheses, vol. 1, New York 1970, pages 802 - 825; Houben-Weyl, Methoden der Organi-schen Chemie, (Methods of Organic Chemistry), volume E5, 25 1985, pages 656 - 773). a) Reaction of a mono- or dicarboxylic acid of the formula I or II in which at least one of the radicals R3 and R3 denotes hydrogen with an appropriate alcohol with acid catalysis (mineral acid or acid 30 ion exchanger). b) Alkylation of a mono- or dicarboxylic acid of the formula I or II in which at least one of the radicals R3 and R3 denotes hydrogen with a compound R3Z or R3Z, in which Z denotes a leaving group which 35 can be displaced nucleophilically (such as halogen. - 20 - tosylate), in a polar protic or dipolar aprotic solvent, in the presence o£ a base such as an alkali metal hydroxide or alcoholate. c) Reaction of a mono- or dicarboxylic acid of the 5 formula I or II in which at least one of the radi cals Ra and R3 denotes hydrogen with a diazoalkene in an inert organic solvent such as CS^Clj.
The nootropic action of the compounds according to the invention has been tested in the inhibitory (passive) 10 avoidance test (step-through model) in mice having a body weight of 20-25 g. A modified form of the test method described by J. KOPP, Z. BODANECKY and M.E. JARVIK has been described by J. BURES, 0. BURESOVA and J. HUSTON in "Techniques and Basic Experiments for the Study of Brain 15 and Behavior", Elsevier Scientific Publishers, Amsterdam (1983) .
According to the statements in this literature, a substance is said to have nootropic activity when it is able to abolish the amnesia induced in the experimental 20 animals by an electroconvulsive shock or the amnesia induced by scopolamine.
The experiments were carried out by modified test methods. The comparison compound used was the known nootropic agent 2-oxo-l-pyrrolidinylacetamide (piracetam). The 25 marked superiority of the compounds according to the invention over the comparison substance was evident from the fact that the scopolamine-induced amnesia in the inhibitory avoidance test can be abolished with an oral MED (minimal effective dose) of 1.0-30 mg/kg. The 30 comparison substance has an oral MED of about 500-1,000 mg/kg.
Most of the compounds according to the invention have only low toxicity. - 21 - By reason of their pharmacological properties, the compounds according to the invention are suitable not only for the treatment of high blood pressure but also for the treatment of cognitive dysfunctions of various 5 etiologies, as occur with, for example, Alzheimer's disease or senile dementia.
Hence the invention also relates to the use of the compounds according to the invention for the treatment and prophylaxis of cognitive dysfunctions in patients 10 with high blood pressure.
The invention furthermore embraces medicaments containing the said compounds, processes for their preparation and the use of the compounds according to the invention for the preparation of medicaments which can be used for the 15 treatment and prophylaxis of the abovementioned diseases.
It is possible, in practicing the method according to the invention, to use the angiotensin converting enzyme inhibitors which are described above in mammals such as monkeys, dogs, cats, rats, humans etc.
The medicaments are prepared by processes which are known per se and familiar to those skilled in the art. The pharmacologically active compounds (•» active compound) according to the invention are used as medicaments either as such or, preferably, combined with suitable pharmaceutical auxiliaries, in the form of tablets, coated tablets, capsules, suppositories, emulsions, suspensions or solutions, the content of active compound being up to about 95%, preferably between 10 and 75%.
The auxiliaries suitable for the desired medicament formulation are familiar to those skilled in the art by reason of their expert knowledge. Apart from solvents, gel-forming agents, suppository bases, tablet ting auxiliaries and other active compound vehicles, it is possible to use, for example, antioxidants, dispersing agents. 20 25 30 - 22 - emulsifiers, antifoam agents, masking flavors, preserva tives, solubilizers or colorants.
The active compounds can, for example, be administered orally, rectally or parenterally (for example intra-5 venously or subcutaneously), oral administration being preferred.
For a form for oral use, the active compounds are mixed with the additives suitable for this purpose, such as excipients, stabilizers or inert diluents, and converted 10 by the customary methods into suitable presentations such as tablets, coated tablets, hard gelatin capsules, aqueous, alcoholic or oily suspensions, or aqueous, alcoholic or oily solutions. Examples of inert vehicles which can be used are gum arabic, magnesia, magnesium 15 carbonate, lactose, glucose or starch, in particular corn starch. This formulation can take the form of dry and of moist granules. Examples of suitable oily excipientB or solvents are vegetable or animal oils such as sunflower oil or fish-liver oil. 20 For subcutaneous or intravenous administration, the active compounds or their physiologically tolerated salts are converted into solutions, suspensions or emulsions, if appropriate with the substances customary for this purpose such as solubilizers, emulsifiers or other 25 auxiliaries. Examples of suitable solvents are water, physiological saline solution or alcohols such as ethanol, propanol, glycerol, and in addition also sugar solutions such as glucose or mannitol solutions, as well as a mixture of the various solvents mentioned. 30 The following examples 1-6 indicate the forms used for the prophylaxis and treatment of cognitive dysfunctions by the method according to the invention. The compounds according to the invention can be converted into the appropriate use forms in analogy to the examples. - 23 - TCyampI o 1 Preparation of the agent used according to the invention for oral use in the treatment and prophylaxis of cognitive dysfunctions. 5 1000 tablets each containing 10 mg of 2-[N- (l-S-carbethoxy-3 -phenylpropyl)-S-alanyl]-lSr 3S,5S-2-azabicyclo[3.3.0]octane-3-carboxylic acid are prepared using the following auxiliaries: 2-[N-(l-S-carbethoxy-3-phenylpropyl)- 10 g 10 S-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane- 3-carboxylic acid corn starch 140 g gelatin 7.5 g microcrystalline cellulose 2.5 g 15 magnesium stearate 2.5 g 2- [N- (l-S-Carbethoxy-3-phenylpropyl)-S-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid and corn starch are mixed with an aqueous gelatin solution. The mixture is dried and milled to from granules. Micro-20 crystalline cellulose and magnesium stearate are mixed with the granules.
The resulting granules are compressed to form 1000 tablets, each tablet containing 10 mg of the ACE inhibitor. These tablets can be used for the treatment and 25 prophylaxis of cognitive dysfunctions.
Firanrpl a 2 In analogy to Example 1, 1000 tablets each containing 10 mgof 1'-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-(3'S, 5'S)-spirobicyclo[2.2.2]octane-2,3'-pyrrolidine-5'-30 carboxylic acid are prepared. t - 24 - Wvawpl p *3 Gelatin capsules each containing 10 mg of l'-[N-(l-S-carbethoxy-3 -phenylpropyl)-S-alanyl]-(3'R,5'S)-spiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' -carboxylic acid 5 are filled with the following mixture: 1'- [N-(l-S-Carbethoxy-3-phenylpropyl)-S-alanyl]-(3'R,5'S) -spirobicyclo [2.2.2] octane-2,3' -pyrrolidine-5' -carboxylic acid 10 mg Magnesium stearate 1 mg 10 Lactose 214 mg These capsules can be used for the treatment and prophylaxis of cognitive dysfunctions.
Example 4 The preparation of an injection solution is described 15 below: 2- [N- (1-S-Carboxy-3-phenylpropyl) -S-alanyl] - (1S,3S,5S) - 2-azabicyclo[3.3.0]octane-2-carboxylic acid 250 mg Methylparaben 5 g Propylparaben 1 g 20 Sodium chloride 25 g Water for injections 5 1 2- [N- (l-S-Carboxy-3-phenylpropyl) - S-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid, the preservatives and sodium chloride are dissolved in 3 1 of water 25 for injections, and the solution is made up to 5 1 with water for injections. The solution is filtered sterile and dispensed aseptically into presterilized vials, which are closed with sterilized rubber caps. Each vial contains 5 ml of solution. 30 Example 5 Tablets which can be used for the treatment or - 25 - prophylaxis of cognitive dysfunctions are prepared as described in Example 1 with the exception that in place of 2-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3S-carboxylic acid 5 use is made of 2-[N-(l-S-carboxy-3-phenylpropyl)-S-alanyl] - (1S,3S,5S) -2-azabicyclo[3.3.0] octane-3-carboxylic acid or 1- [N-(l-S-carboxy-3-phenylpropyl)-S-alanyl]-(2S,3aR,7aS)-octahydroindole-2-carboxylic acid or 1- [N-(1-S-carbethoxy-3-phenylpropyl)-S-alanyl] -cis-10 2,3,3a, 4, 5,7a-hexahydro[1H] indole-2-S-endo-carboxylic acid or 1-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-cis-2,3,3a,4,5,7a-hexahydro[1H]indole-2S-endo-carboxylic acid or 2-[N-(l-S-carboxy-3-phenylpropyl)-S-lysyl]-(IS,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid or 15 2- [N- (l-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-IS,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid or N- (l-S-carboxy-3-cyclohexylpropyl)-S-lysyl-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid or l'-[N-(l-S-carbethoxy-3 -phenylpropyl)-S-alanyl]-exo-spirobicyclo-20 [2.2.2]octane-2,3'-pyrrolidin-5'-S-ylcarboxylic acid or (S, S,S)-1-methyl-2-(1-carbethoxy-3-phenylpropyl)-2H-undecahydrocyclopenta [4.5] pyrrolo [1,2-a] pyrazine-3, 8-dione or 1' - [N- (l-S-carbethoxy-3-phenylpropyl) -S-alanyl] -endo-spirobicyclo[2.2.2]octane-2,3'-pyrrolidin-5'-S-25 ylcarboxylic acid.
Example 6 An injection solution is prepared in analogy to the procedure described in Example 4 with the exception that in place of 2-[N-(l-S-carbethoxy-3-phenylpropyl)-S-30 alanyl] - (1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid use is made of 2-[N- (l-S-carboxy-3-phenylpropyl) -S-alanyl] - (1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid or 1-[N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-(2S,3aR,7aS)-octahydroindole-2-carboxylic acid hydro-35 loride or 1-[N-(l-S-carboxy-3-phenylpropyl)-S-alanyl]-(2S,3aR,7aS)octahydroindole-2-carboxylic acid or 1- [N- (1-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-cis- - 26 - 2,3,3a, 4,5,7a-hexahydro [1H] indole-2-S-endo-carboxylic acid or 1-[N-(l-S-carboxy-3-phenylpropyl)-S-alanyl]-cis-2,3, 3a,4,5,7a-hexahydro [1H] indole-2-S-endo-carboxylic acid or 2-[N- (l-carboxy-3-phenylpropyl)-S-lysyl] -5 (1S,3S,5S)-2-azabicyclo[3.3.0.]octane-3-carboxylic acid or 2- [N-(l-S-carbethoxy-3-cyclohexylpropyl)-S-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid or 2- [N- (l-S-carboxy-3-cyclohexylpropyl)-S-lysyl]-(IS,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid or 10 1' - [N- (l-S-carboxy-3-phenylpropyl) -S-alanyl] -endospiro-bicyclo [2.2.2] octane-2,3' -pyrrolidine-5' -S-carboxylic acid or 1' - [N- (l-S-carboxy-3-phenylpropyl) -S-alanyl] -exospirobicyclo[2.2.2]octane-2,3'-pyrrolidine-5'-S-carboxylic acid. 15 The Examples 7-95 which now follow are intended to illustrate the process according to the invention for the preparation of the new compounds of the formula I and III, without confining the invention to them.
Example 7: 20 Oc tadecvl 2-[N-(IS)-ethoxvcarbonvl-3-phenylpropyl)-S-ala-nvll-cis.endo-2-azabicycloT3.3.01 octane-3-S-carboxvlate 23 g of octadecyl cis,endo-2-azabicyclo[3.3.0]octane-3-carboxylate prepared in analogy to European Patent A-79022 are reacted with 6.7 g of HOBt, 13.8 g of N- (IS) -25 carbethoxy-3-phenylpropyl)-S-alanine and 10.2 g of dicyclohexylcarbodiimide in 200 ml of dimethylformamide. After stirring at room temperature for 3 hours, the precipitated dicyclohexylurea is filtered off with suction, the filtrate is concentrated, the residue is 30 taken up in 1 1 of ethyl acetate, and the solution is extracted by shaking with 3 x 500 ml of 5% strength NaHCO, solution. The organic phase is concentrated and chromatographed on a column of 1 kg of silica gel with ethyl acetate/petroleum ether in the ratio 2:1, and in 35 this way is separated into the title compound and the diastereomeric (S,S,R) compound. - 27 - Example 8: 1- [N- (IS) -Dodecvloxvcarbonvl-3-phenvlpropvl) -S-alanvll - 2S.3aR.7aR-octahvdroindole-2-carboxvlic acid a) Benzvl 1 - fN- (IS) -dodecvloxvcarbonvl-3-phenylpropyl) -5 S-alanvl1 -2 S.3 aR.7 aR-oc tahvdroindole-2-carboxvlate 10 mmol of benzyl S-alanyl-2S,3aR,7aR-octahydro-indole-2-carboxylate (prepared as in European Patent A-84164) are dissolved in 30 ml of anhydrous etha-nol. Ethanolic potassium hydroxide is used to adjust 10 the pH of the solution to 7.0, and 1 g of powdered molecular sieve (4A), and then 10 mmol of dodecyl 2-keto-4-phenylbutyrate, are added. A solution of 1 g of sodium cyanoborohydride in 10 ml of anhydrous ethanol is slowly added dropwise. After a reaction 15 time of 20 hours at 20 to 25 °C, the reaction solution is filtered, and the solvent is removed by distillation. The residue is taken up in ethyl acetate/water. After the ethyl acetate phase has been evaporated, the residue is chromatographed on 20 silica gel with ethyl acetate/cyclohexane (1:4). b) The compound obtained as in a) is hydrogenated in ethanol in the presence of palladium/animal charcoal (10%) at 20-25°C under atmospheric pressure. After the catalyst has been removed, 0.5 N ethanolic 25 hydrogen chloride is added to the solution until it gives an acid reaction. The solution is concentrated in vacuo, and the residue is crystallized by trituration with diisopropyl ether.
Example 9: 30 Isobutvl 2-fN-[(2S)-ethoxvcarbonvl-3-phenvlpropvll-L-ala-nvll -(IS.3S.5S^ r-ynio T3 .3 .01 octane-3-carboxvlate 2.00 g (4.80 mmol) of 2-[N- [ (IS) -ethoxycarbonyl-3-phenyl-propyl] -L-alanyl] - (1S,3S,5S) -2-azabicyclo [3.3.0] octane-3-carboxylic acid were dissolved in 100 ml of isobutanol. - 28 - 0.1 ml of concentrated sulfuric acid was added, and the mixture was boiled under reflux for 15 hours. After cooling, the solvent was removed in a rotary evaporator, and the residue was taken up in methylene chloride. This 5 solution was washed once with water, once with saturated aqueous NaHCO, solution and again with water, dried over MgS04, and concentrated, and impurities were removed by chromatography on 200 g of silica gel (mobile phase methylene chloride/ethyl acetate 8:2). 10 Yield 0:51% of theory of oily product. [a]" « -28.2° (c ■ 1, methanol) This product was dissolved in ether, the pH was adjusted to 2 with saturated ethereal hydrochloric acid, the solvent was evaporated off, and the residue was crystal-15 lized from diisopropyl ether.
Data on the hydrochloride: Melting point 123 - 124°C [a]" ■ +17.7° (c - 1, methanol) Example 10: 20 Benzhvdrvl 2-TN-T(IS)-ethoxvcarbonvl-3-phenvlpropvn-L-alanvll - (IS. 3S. 5S) ^vclo [3 .3 .01 octane-3-carboxv- late 2.07 g (4.97 mmol) of 2- [N-[(IS)-ethoxycarbonyl-3-phenyl-propyl] -L-alanyl] - (1S,3S,5S) -2-azabicyclo [3.3.0] octane-3 -25 carboxylic acid were dissolved in 50 ml of acetone and, while cooling in ice, a solution of 1.16 g (5.98 mmol) of diphenyldiazomethane in 50 ml of acetone was added dropwise. The solution was then stirred at room temperature for 26 hours, the solvent was evaporated off 30 in a rotary evaporator, and the residue was purified by flash chromatography on 150 g of silica gel (mobile phase toluene/ethanol 98:2).
Yield: 2.55 g (88 %) of oily product [«]" ■ -33.8° (c - 1, methanol). - 29 - KvaTnpl** 11; Oetadecvl 2- fN- (IS) -ethoxvcarbonvl-^-p>"*"ylpropvl1 -L-ala- nvll - (1S.3S.5S) -2-azabicvclor3.3.01o"*-*«"*»-3-carbo3cvlate 2.08 g (5.00 mmol) of 2-[N- t (IS) -ethoxycarbonyl-3-phenyl-5 propyl] -L-alanyl] - (1S,3S,5S) -2-azabicyclo [3.3.0] octane-3 -carboxylic acid were dissolved in 25 ml of absolute dimethylformamide, 1.00 g (10.0 mmol) of potassium bicarbonate was added, and the mixture was stirred at 40°C for 90 minutes. After cooling to room temperature, 10 a solution of 4.00 g (12.0 mmol) of 1-bramooctadecane in 20 ml of absolute dimethylformamide was added dropwise, and the mixture was stirred at 40°C for 4 hours. The solvent was removed in a rotary evaporator at about 1 torr, and the residue was partitioned between water and 15 methylene chloride. The organic phase was separated off, dried over MgS04 and concentrated. 3.05 g (92 %) of the product were isolated from the crude product (5.40 g) after column chromatography on 200 g of silica gel (mobile phase toluene/ethanol 99:1). 20 [a]" s -19.6° (c s l, methanol) Bvamplo 12: Benzvl 2- fN- T (IS) -benzvhvdroloxvcarbonvl-3-r>hf»nylpropvl1 -L-alanvll - (1S.3S.5S) cvclo[3.3.01 octane-3-carboxv- late 25 a) Benzhvdrvl (2R)-hydroxy-4-phenvlbutvrate A solution of 10.1 g (52.1 mmol) of diphenyldiazo-methane in 400 ml of absolute acetone was added dropwise over 20 minutes to a solution of 7.40 g (41.1 mmol) of (2R)-hydroxy-4-phenylbutyric acid in 30 200 ml of absolute acetone while cooling in ice, and the reaction mixture was stirred at room temperature for 20 hours. The solvent was evaporated off, and the residue was tirturated with 100 ml of petroleum ether. 6.4 g of crystalline product were obtained. 35 The mother liquor was concentrated, and a further 6.0 g of the product were isolated by column - 30 - chromatography on 700 g of silica gel (mobile phase toluene/ethanol 99:1).
Total yield: 12.4 g (87 %).
Melting point 88 - 89°C. [<*]" « -1.8° (c ■ 5, methanol).
Benzvl 2- [W- f (IS) -benzhvdrvloxvcarbonvl-3 -phenyl-propyl!-L-alanvll-(1S.3S.5S)-2-azabicyclo[3.3.01 -octane-3-carboxvlate 1.80 g (4.33 mmol) of benzyl 2-(N-tert.butoxy-carbonyl -L-alanyl] -(1S,3S,5S)-2 -azabicyclo-[3.3.0]octane-3-carboxylate were dissolved in 4.5 ml of trifluoroacetic acid, and the reaction solution was stirred at room temperature for 90 minutes. It was then concentrated and, to remove trifluoroacetic esters, toluene was evaporated off three times in a rotary evaporator. The residue, which comprised 1.90 g of benzyl 2-(L-alanyl]-(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylate trifluoroacetate, was dissolved in 10 ml of absolute methylene chloride (solution A). 1.63 g (4.71 mmol) of benzhydryl (2R)-hydroxy-4-phenylbutyrate from Example 12 a) were dissolved together with 0.4 ml of absolute pyridine in 25 ml of absolute methylene chloride and, at -10°C, 1.41 g (5.00 mmol) of trifluoromethanesulfonic anhydride were added dropwise within 20 minutes. The cooling bath was then removed and, after room temperature had been reached, the solvent was evaporated off. The residue was filtered through 50 g of silica gel using methylene chloride, and the filtrate was concentrated. 1.70 g of benzhydryl 4-phenyl-(2R)-trifluoromethylsulfonyloxy butyrate were obtained and were dissolved in 10 ml of absolute methylene chloride (solution B). - 31 - b3) 1.0 ml (7.40 mmol) of triethylamine was added to solution A and then, at 0°C, solution B was slowly added dropwise. The cooling bath was removed and the reaction solution was stirred at room temperature for 19 hours, then washed three times with water, dried over MgS04 and concentrated. The residue was purified by chromatography on 80 g of silica gel (mobile phase cyclohexane/ ethyl acetate 8:2 and 7:3), and 0.95 g (30%) of the desired product was obtained.
Melting point 81-85°C. [a]" ■ -55.2° (c ■ 1, methanol) By suitable combinations of the methods described in the foregoing examples, the following additional compounds are prepared (the designation of the ring systems corresponds to that for the compounds of the formulae I and II): - 32 - r'ooc - ?4 - H - C -CH - HH - 15 » • R 0 CH, CH — CE« i 2 2 COOR - CH. :-0 Example s'00c-CH-K-S*B5 R2 R1 13 Ring system A -c3h5 -ch (ch,), 14 Ring system B "cjh, -chj-ch{ch,)2 15 Ring system C -ch, -°v 16 Ring system C -c,h, -ch^.h,), 17 Ring system D "cjh5 •o 18 Ring system D "cjhs O 19 Ring system D -cjhs & 20 Ring system D "cjhs <°Xo> 21 Ring system D -c3h5 22 Ring system D -c3h5 -(ch2 ),.<§> 23 Ring system B "CjHJ - (ch,) j - chj 24 Ring system F -ch, -ch(c,hs), 25 Ring system 6 ~cjhs -ch (ch,), R Exi 26 27 28 29 30 31 32 33 34 35 36 37 38 39 - 33 - • t * - CH - N - C -CH - KH - CE - CH, - CB- I* 5 il, - COOf? 2 R 00C-CH-H- ?*-! R4 R' R* Ring system G -c2h5 -ch{c,hs), Ring system S -c,h5 -(ch2)2-© Ring system H c,h, -ch (ch,), Ring system h c,h5 -ch2-ch(ch,), Ring system h c5h5 - (chj) 5-chj Ring system h CjH, o Ring system h c,hs -©-CH, Ring system h CjH, Ring system h cjh, Ring system h h -ch2H§> Ring system h CjH5 -ch(c,h5), Ring system h c,h5 - Ring system J c,h, -ch (c,h,) j Ring system K c2as -(ch,)4-ch, - 34 - r5ooc B - H - C -CH - HH - j.5 >1 T R 0 CH, CH - CH, 1 2 2 coor - ch* Example r3ooc-ch-n- '4 • 5 r4 r Ra RJ 41 Ring system L C3H5 -C (CH,), 42 Ring system M c,h5 - (CH,) ,-CH (CH,), 44 Ring system N C,HS -CH (CH,) 2 45 Ring system 0 c,h5 46 Ring system P CjH, -o 48 Ring system A CH2CH (CHj) j -oh2-© 49 Ring system B CH(CHj) , -C (CH,), 50 Ring system C CH(C4H5)a -H 51 Ring system D ch2- -ch2-® 52 Ring system D CHj-CH (CH,) 2 -ra2-© 53 Ring system D CH2-CH(CHj) j -h 54 Ring system D CHj-CH (CH,) j -CH (C,HS) a 55 Ring system O CH(C,H,)j -C (CH,), 56 Ring system D CH(C,Hs)j -h - 35 - R300C E H - C -CH - HH ?5 II T R 0 CH, CH - CH- i 2 2 coor - CH, Example R300C-fH-N-R4 R5 Ra RJ 57 Ring system B -@m*3 - (CHj) 5-CHj 59 Ring system G -CH (C(H,) j -cv® 60 Ring system G -CH(C,HS), -C (CH,), 61 Ring system H -CH2CH (CH,) j -ch2-@ 62 Ring By stem H -CHjCH (CH,) 2 -H 63 Ring system H -CHjCH (CH,) 2 -CH(C,H5), 64 Ring system H -ch2- CM M U 1 -C (CH,), 66 Ring system H -CH(C,H,)J -°h2-@ 67 Ring system H -CH (C,H,) j -H 68 Ring system H -CH (C(H,), -C (CH,), 69 Ring system H -CH(C,H5)a -CH(C,H,)a 70 Ring system I ■o 71 Ring system J - (CH,) s - CH, -CH (C,HS) 2 - 36 - , ♦ « « ROOC - p - K - C -^H - HH - CH - CH2 - CH2 R4 k5 0 CEj COOR2 Example r300c-ch-n- ' A 1 5 ra r5 Ra R* 72 Ring system R o -™2-© 73 Ring system L -cb2-(g) - (CHj) , - CHj 74 Ring system M - (CH2)3-CH-(CH,), -CH (C(HS) 2 75 Ring system M -CH (C(HS) 2 -C (CH,) j" CHj CHj 76 Ring system 0 -CH(CHj) 3 -CH (C«H,) a 77 Ring system P -CH (CH,) j -C (CH,), 78 Ring system Q -C (CH,) j (91 CM W O 1 78a Ring system D C2H, menthyl 7 8b Ring system S menthyl CHjCeH5 83 CH3°> ho COOR^ ^ CH2-COOR3 Example Yl RJ RJ 87 CH, -CjH5 -CH (C(HS), 89 CH, -CH,-CH (CH,), -CH2" Qp • t /"^hh - ch - ch2 - ce2 - r OOC coor Example RJ R* 90 -CH(C,H5), -C (CH,), 91 -CH^H,), -CH(C,H,), Example 92 10 4- [N- (IS)-Carboethoxy-3-phenylpropyl)-S-benzyl] -exospiro(bicyclo[2.2.2]octane-2,3-pyrrolidine)- 5 -carboxylic acid a) N- (IS-Carbethoxy-3-phenylpropyl)-S-laurvlbenzvl ester 15 3.4 g (10 mmol) of ethyl 2- (D) -trifluoromethyl- sulf onyloxy-4-phenylbutyrate and 5.9 g (15 mmol) of the benzyl ester of L-leucine tosylate were mixed in 50 ml of abs. CH2C12 and, after addition of 4.2 ml of triethylamine, the mixture was stirred at room 20 temperature for 6.5 hours. After concentration of - 38 - the solution, the product was isolated by column chromatography (silica gel, cyclohexane/ethyl acetate 9:1). 3.2 g of colorless oil were obtained. JH-NMR 6 = 0.95 (d, CHj), 1.2 (t, CH3) 1.8 (m, CHa) 2.6 (m, CHa) 3.3 (m, CH) 4.1 (g, CH,) 5.1 (s, CH3) 7.3 (s, CH) ppm.
N- (l-S-Carboethoxv-3-phenylpropyl)-S-leucine 3.1 g of the benzyl ester obtained in a) were cleaved by hydrogenolysis with 500 mg of Pt/C (10%) in 200 ml of ethanol. After removal of the catalyst by filtration and concentration of the solution, 2.3 g of colorless crystals of the carboxylic acid of melting point 120-121°C were obtained. ^-NMR 6 = 0.9 (d, CH,), 1.25 (t, CH3) , 1.8-2.1 (m, CH2) , 2.7 (m, CH2) , 3.3 (q, CH) , 4.25 (q, CHa) , 7.2 (s, CH) ppm. 4- [N- (IS) -Carbethoxy-3-phenylpropyl) -S-leucvll -exo-spirobicvclo[2.2.21 octane- 2.3-pyrrolidine- 5 -carboxylic acid 2 g (6.2 mmol) of N- (l-S-carboethoxy-3-phenylpropyl) -S-leucine and 1.9 g (3.9 mmol) of benzyl exo-spiro(bicyclo[2.2.2]-octane-2,3 -pyrrolidine)-5-carboxylate were stirred in 100 ml of dime thy lformamide with 4.3 ml of triethylamine and 6.5 ml of n-propylphosphonic anhydride at room temperature overnight. The reaction solution was taken up in ethyl acetate and shaken twice with aqueous NaHC03 solution and once each with 10 % aqueous citric acid, saturated aqueous NaHC03 solution and saturated aqueous NaCl solution. The organic phase was then separated off, dried and concentrated. The crude product, with a yield of 2.8 g, was separated into the two diastereomers by column chromatography (silica gel, toluene/ethyl acetate 95:5). 1 g of pure product was obtained for each benzyl ester. 1 g of the first diastereomer was hydrogenated with Pd/C in 40 ml of ethanol. 780 mg of crystalline carboxylic acid of melting point 131-132°C were obtained.
Rotation [a]" = - 39 --2.8° (c = 1, methanol) 860 mg of the second diastereomer were hydrogenated with Pd/C in 35 ml of ethanol and, after removal of the catalyst by filtration and concentration of the 5 solution, the yield was 720 mg.
Melting point: the substance sinters above 65°C Rotation [a]" = -22.2° (c = 1, methanol) Example 93 4-[N-(IS)-Carboxyl-3-phenylpropyl)-S-leucyl]-exo-10 spiro (bicyclo [2.2.2] octane-2,3-pyrrolidine) -5-carboxylic acid 102 mg (0.2 mmol) of the carboxylic acid from Example 92c) were stirred in aqueous 4N KOH solution until all the substances had dissolved. The solution was applied to 15 an ion exchanger ( Rotation [a]" = 4-3.9° (c = 1, methanol) The following compounds of the formula II are prepared in 20 analogous manner (the designations of the ring systems correspond to those for the compounds of the formulae I and II): - 40 - HOOC -CH-N-C -CH-NH-CH- CHa -CH2 -o R4 R5 0 R1 COOCjHj HOOC - CH - NH I' CH(CHj)2 a CE(CH5)CH2CH3 a ch2c6h5 a CE2-C6Bn (CE2-Cyclohexyl) C ce2—cgc4 ocej g CK2-C6E4 0C2E^ C ce2-c6e4-oc3b7 c ce2-c6e4-oc4b9 a (ce2)4-kh2 j) (ce2)5-nk2 a ce2-ce2- s ce5 a - 41 - * HOOC -CH-N-C -CH-NH-CH- CH2 -CHa I, 's 11 'x 1 R R5 O R1 COOCjH5 R1 HOOC - CH - NH I, I, R R5 ce(ch3)2 B ch(ch3)ce2ce3 B ce2c6b5 B ce2-c6e11 D ce2-c6e4-oce3 H ce2—cge^~ 0c2e^ g ce2—c^e on-c^b-y g c"2 ""cge^— on-c^ng c (ce2)4-nh2 c (CE2)3-rr:2 g ch2-ce2-s-ce5 D - 42 - HOOC -CH-N-C -CH-NH-CH- CHa -CHa L 11 'x 1 R R5 0 R1 COOCjHg R1 HOOC - CH - NH ce(ce3)2 c ce(cb3)ch2ch3 c ch2cge^ c CE2-CgE^^ £ ce2-c6e4-oce3 i ce2-c6e4- oc2e5 h CE2-C6E4-On-C5E7 E ch2-c6e4-°n-c4b9 g (ce2)4-nh2 g (ch2 )j-ke.2 e ck2-ch2-s-ce5 e - 43 - HOOC - CH-N-C -CH-NH-CH - CH2-CH2 l i. 1 K 1 R4 R5 0 R1 COOC2H5 R1 HOOC - CH - NH 1 ch(ch3)2 d ch(ch3)ce2ce3 d ce2c6e5 d ch2"c6h11 p ce2-c6e4-oce3 k ce2-c6e4-oc2e5 i ce2 -cge4—on-c^ey i on-c^hg e (ce2)4-f£2 h (ce2)3-he2 0 ceg-chg- s-ch3 i - 44 - HOOC -CH-N-C -CH-NH-CH- CHj -CHj I. I. I l. I R4 R5 O R1 COOCjH5 Rl HOOC - CH - NH R4 R5 ck(ch3)2 g ce(ch3)ce2ch3 s ch2c6h5 e CK2~C6E11 G CE2 —CgE4~ OCE^ 0 ce2-c6e4-oc2h5 e ce2 -cge4-on-cjey v ck2-c6econ-c4e9 j (ce2)4-ke2 h (ch2)3-i7e2 ? ce2-ce^- s"cej p - 45 - HOOC - CH - N - C - CH - NH - CH - CHj - CH2 i4 is I I, I R4 R5 0 R1 COOCjH5 HOOC - CH - NH cf.(ch3)2 b CH(CE3)CE2CE3 p ch2c6b5 i ce2~c6h11 e cb2-c6e4- oce3 ? cb2-c6e4-oc2e5 0 ce2*cge4— Oxi—c^by 0 CE2-C6E4-On-C4E9 n (ce2)4-ne2 q (^^2)3-NE2 q ch2-ce2-s ce3 q - 46 - * HOOC - CH - N - C - CH-NH-CH - CH2 - CHj '« 1 'i 1 R4 R5 O R1 COOCaH5 R1 HOOC - CH - NH l4 I.
R4 R5 ch(ch3)2 i ch(ch3)ch2ch3 6 ch2c6h5 n ck2- c6h, 1 i ck2'c6h4-°ch3 q ce2~c6h4"0c2h5 p CE2-C6E4-0n-C3K7 p CE2-C6H4-0a-C4Eg 0 (CH2)4-NE2 ? CE2-CH2-S-CE3 n - 47 - HOOC -CH-N-C -CH-NH-CH - CH2-CH2 R4 R5 0 Rl COOCJH5 HOOC - CH - NH I- ce(ch3)2 0 ch(ch3)ch2ch3 e ch2c6e5 0 CVc6e11 l q ch2-cgh4- on-cjhy q ce2-~cgh£- on—c^eg ? cn2— ce2~ s "coj g - 48 - HOOC -CH-N-C -CH-NH-CH- CHa -CHj <0 R4 R5 O R1 COOC,H 2 5 R1 HOOC - CH - NH !• i- ch(ch3)2 ? ch2-c6h5 p ch2"c6e11 m ch2"c6e4-°ch3 d ch2-c6h4-oc2e5 d ch-2"fccge^^ on*c jhy e ce2-c6e4-°n-c4e9 q - 49 - HOOC -CH-N-C -CH-NH-CH - CH2 - CH2 o '< '5 11 K i R4 R5 0 R1 COOCjH5 R1 HOOC - CH - NH j. L> ch(ch3)2 h CK(CH3)CH2CH3 ? CH2-C6E5 q CHg-CeH^ H CE2-C6Ia-On-C4S9 D CH(CH3)CE2CH5 q CE(CE3)CE3CE 3 I ch2"C6E11 0 CK2"C6B11 Q Example 94; 1- [N- (IS) -Carboethoxybutyl) -S-alanyl] -octahydrocyclo-10 penta[b]pyrrole)-2-carboxylic acid a) Ethvl PL-2-trifluoromethvlsulfonvloxvpentanoate 5 g (34 mmol) of ethyl 2-hydroxyvalerate and 2.85 g (35.9 mmol) of absolute pyridine were dissolved in 100 ml of absolute CH2C12 under protective gas, the 15 solution was cooled to 0°C and 9.66 g (34 mmol) of trifluoromethanesulfonic anhydride were added. The mixture was warmed to room temperature and stirred for 6 hours. The solution was concentrated and the resulting crude product was purified by column 20 chromatography (silica gel, petroleum ether/CHjCl, 6:1). The yield was 9.3 g of a colorless, slightly viscous liquid.
IR: 2880 - 3000 1770, 1420, 1200 - 1220 1150, 620 cm*1 - 50 - Benzyl ester of N-(1-S-carboethoxvbutvl)-S-alanine 4.9 g (17.6 mmol) of the trifluoromethanesulfonic ester thus obtained were dissolved, under nitrogen, in 70 ml of absolute CH2C13 with 4.08 g of the benzyl ester of L-alanine hydrochloride (19 mmol) with the addition of 5.4 ml of triethylamine, and the solution was stirred at room temperature for 3 hours. It was then concentrated, the crude product was taken up in ethyl acetate, and the solution was washed three times with water, dried and concentrated. The diastereomers were separated by column chromatography (silica gel, cyclohexane/ethyl acetate (5:1). The yield of each isomer was 500 mg. The diastereomer isolated in the first filtration had the S,S configuration. lH NMR = 0.9 (*tCE3)f 1.3 1.35 (d»CB3)» 1-4 (id,CE2)» 1.6 (c,CE2), 1.9 (B,ffE)t 3-3 (t,CE), 3.4 (q,CE), 4.2 (m,CE2), 5.15 (q,CE2 ?h)» 7.4 (ef CE aromat.) ppjc.
N- (1-S-Carboethoxvbutvl)-S-alanine 600 mg (1.95 mmol) of benzyl ester (diastereomer A) were hydrogenated with Pd on charcoal in 34 ml of ethanol. The catalyst was then filtered off, and the solution was concentrated in vacuo. The product was then obtained as a white solid with a melting point of 137° and a yield of 430 mg. 430 mg (1.98 mmol) of N-(1-S-carboethoxybutyl)-S-alanine and 486 mg (1.98 mmol) of benzyl L(-)-octahydrocyclopenta [b]pyrrole-2-carboxylate were dissolved, under nitrogen, in 20 ml of dimethylformamide, the solution was cooled to -10°C, and 1.5 ml of triethylamine and 2 ml of n-propylphos-phonic anhydride were added. The solution was stirred at -10°C for 1 hour and then at room temperature overnight. It was then taken up in 200 ml of ethyl acetate and washed with saturated aqueous - 51 - NaHCOj solution 10% aqueous citric acid and saturated aqueou NaCl solution. After the solution had been dried and concentrated, the diastereomeric compounds were separated by column chromatography 5 (silica gel, eyelohexane/ethyl acetate 9:1). The yield was 360 mg. Both diastereomers were hydrogen-ated with Pd/C in ethanol as described in Example 94 c) and, after concentration of the solution, they were obtained as white solids. 10 Example 95: 1- [N- (IS) -Carboxybutyl) -S-alanyl] - (octahydrocyclopenta-[b]pyrrole)-2-carboxylic acid 60 mg (0.17 mmol) of carboxylic acid (Example 94 d) were stirred into 2 ml of 4 N aqueous KOH solution until the 15 substance had completely dissolved. The solution was then applied to a strongly acid ion exchanger and eluted with a 2% strength solution of pyridine in water. The yield after concentration of the solution was 39 mg.
In analogy to the compounds prepared in Examples 94 and 20 95, it is possible to synthesize the following additional compounds of the formula II E r^ooc -ch-n-c-ce-n-ce (ce2)n-r I i I p I 1 4 ^ 5 r4 r5 0 r1 c00r2 which, witimn = 2, R1 is CH]( R3 is C3H5, R3 is H, and R 3 ® and the part of the molecule r 00c-ce-n « A r4 r3 25 are substituted as indicated in the table detailed below. - 52 - EDOC-CE-KE R* R5 chj a -ce2ch2ch3 a -(ch2)9-ch3 c 2-Haphthyl D 4-Biphenylyl a -(ce2)13-ch3 a hooc-ch-hh R4 k5 ch3 b -ce2ce2cb3 b -(ch2)9-ce3 d 2-Nephthyl p 4-Biphenylyl c -(ch2)13-ch3 b hooc-ch-hh i y »5 r4 r ch3 c -ch2ch2ch3 c -(ch2)9-ch3 g 2-Naphthyl G 4-Biphenylyl D -(ce2)13-ch3 c 53 - HOOC-CH-HH r* r5 CH3 D -CH2CH2CH3 D -(CE2)9-CH3 H 2-Naphthyl H 4-Biphenylyl H —(CE2)^3—Ca3 £ HOOC-CH-NH R* i.5 1 o ch3 g -ce2ce2ch3 g -(ce2)g-ce3 k 2-Naphthyl I 4-Biphenylyl I 15 -(ch2)13-ce3 g HOOC-CH-HH *4 '5 R4 R CE3 • E -CE2CE2CE3 E -(CH2)9-CE3 N 2-Naphthyl M 4-Biphenylyl H — (CK2)^ 3—CE3 N - 54 - h hooc-ch-hh ±4 *5 ch3 n -ch2ce2ch3 k —(CH2)g—CH3 0 5 2-Naphthyl H 4-Biphenylyl P -(ce2)13-ch3 0 r hooc-ch-hh i4 p5 CKj Q -ce2ce2cb3 q -(ce2)9-ce3 p 4-Biphenylyl Q —(cb2)^3—chj p hooc-ch-hh r4 r5 chj p -ch~ch,ch, ^ 2 2 p -(ch2)s-ch3 q 4-Biphenylyl c- -(ch2)13-ch3 q 4-Biphenylyl h - 55 -
Claims (3)
1. l-S-carbethoxy-3 -phenylpropyl)-S-alanyl]-cis,endo-lH-2,3,3a,4,5,7a-hexahydroindole-2-S- or -
2. -R-car-boxylic acid. The use as claimed in claim 1, wherein use is made of 1'- [N-(l-S-carbethoxy-3-phenylpropyl)-S-alanyl]-exo/endo- spirobicyclo [2.2.2] octane-2,3' -pyrrolidines'-carboxylic acid, 1'[N-(l-S-carbethoxy-3-phenyl-propyl) -S-alanyl]-(3'S,5'S)-spirobicyclo[2.2.2]-octane-2,3'-pyrrolidine-5'-carboxylic acid, l'-[N-(l-S-carbethoxy-3-phenylpropyl) -S-alanyl] - (3'S,5'R) -spirobicyclo [2.2.2]-octane-2,3'-pyrrolidine-5' -carboxylic acid, 1'-[N-(l-S-carbethoxy-3-phenyl-propyl)-S-alanyl] -(3'R,5'S)-spirobicyclo [2.2.2] -octane-2,3'-pyrrolidine-5'-carboxylic acid, l'-[N-(l-S-carbethoxy-3-phenylpropyl) -S-alanyl] - (3'R,5'R) -spirobicyclo [2.2.2]octane-2,3'-pyrrolidine-5'-carboxylic acid, 1'-[N-(l-R-carbethoxy-3-phenyl-propyl)-S-alanyl] -(3' S,5'S)-spirobicyclo [2.2.2]-octane-2,3'-pyrrolidine-5'-carboxylic acid, 1' - [N- (l-R-carbethoxy-3-phenylpropyl)-S-alanyl]-(3'S,5'R)-spirobicyclo[2.2.2]octane-2,3'-pyrrolidine- 5'-carboxylic acid, 1'- [N-(l-R-carbethoxy-3- - 57 - phenylpropyl)-S-alanyl]-(3 ' R, 5' S)-spirobicyclo-[2.2.2]octane-2,3'-pyrrolidine-5'-carboxylic acid, 1' - [N- (l-R-carbethoxy-3-phenylpropyl)-S-alanyl]-(3•' R, 5 ' R) - spirobicyclo [2.2.2] octane-2 , 3 ' -pyr-5 t rolidine-5'-carboxylic acid, 1' - [N-(1-S-carbethoxy-
3. -phenylpropyl)-R-alanyl]-(3'S,5'S)-spirobicyclo-[2.2.2]octane-2,3'-pyrrolidine-5'-carboxylic acid, 1' - [N- (1-S-carbethoxy-3-phenylpropyl) -R-alanyl] -(3'R,5'S)-spirobicyclo[2.2.2]octane-2,3'-pyrrolidine- 5' -carboxylic acid, 1' - [N- (l-S-carbethoxy-3-phenylpropyl)-R-alanyl]-(3'S,5'R)-spirobicyclo-[2.2.2]octane-2,3'-pyrrolidine-5'-carboxylic acid, 1' - [N- (l-S-carbethoxy-3-phenylpropyl) -R-alanyl] -(3'R,5'R)-spirobicyclo[2.2.2]octane-2,3'-pyrrolidine -5' -carboxylic acid, 1'-[N-(l-R-carbethoxy-3-phenylpropyl) -R-alanyl] - (3' S, 5' S) -spirobicyclo-[2.2.2]octane-2,3'-pyrrolidine-5'-carboxylic acid, 1' - [N- (l-R-carbethoxy-3-phenylpropyl)-R-alanyl]-(3' R, 5' S)-spirobicyclo[2.2.2]octane-2,3'-pyrrolidine- 5'-carboxylic acid, 1'- [N-(l-R-carbethoxy-3-phenylpropyl) -R-alanyl] - (3'S, 5'R) -spirobicyclo-[2.2.2]octane-2,3'-pyrrolidine-5'-carboxylic acid or 1' - [N- (l-R-carbethoxy-3-phenylpropyl)-R-alanyl]-(3'R,5'R)-spirobicyclo[2.2.2]octane-2,3'-pyrrolidine -5' -carboxylic acid. F. R. KELLY & CO., AGENTS FOR THE APPLICANTS. 10 15 20 25
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19863610391 DE3610391A1 (en) | 1986-03-27 | 1986-03-27 | COMPOUNDS WITH NOOTROPPER ACTION, THESE CONTAINERS AND THEIR USE IN THE TREATMENT AND PROPHYLAXIS OF COGNITIVE DYSFUNCTIONS |
Publications (2)
Publication Number | Publication Date |
---|---|
IE870784L true IE870784L (en) | 1987-09-27 |
IE62456B1 IE62456B1 (en) | 1995-02-08 |
Family
ID=6297417
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IE78487A IE62456B1 (en) | 1986-03-27 | 1987-03-26 | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfunctions |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP0243645B1 (en) |
JP (1) | JPS62240698A (en) |
KR (1) | KR870008841A (en) |
CN (1) | CN1031267C (en) |
AT (1) | ATE102954T1 (en) |
AU (1) | AU621278B2 (en) |
CA (1) | CA1341064C (en) |
CS (2) | CS212687A3 (en) |
DD (1) | DD280765A5 (en) |
DE (2) | DE3610391A1 (en) |
DK (1) | DK172221B1 (en) |
EG (1) | EG18175A (en) |
ES (1) | ES2061447T3 (en) |
FI (1) | FI91876C (en) |
HU (2) | HU202118B (en) |
IE (1) | IE62456B1 (en) |
MA (1) | MA20919A1 (en) |
NO (1) | NO178546C (en) |
NZ (1) | NZ219764A (en) |
OA (1) | OA08506A (en) |
PH (1) | PH27210A (en) |
PT (1) | PT84564B (en) |
RU (1) | RU1836335C (en) |
TN (1) | TNSN87045A1 (en) |
ZA (1) | ZA872230B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231084A (en) * | 1986-03-27 | 1993-07-27 | Hoechst Aktiengesellschaft | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons |
US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
AU612137B2 (en) * | 1987-04-27 | 1991-07-04 | E.R. Squibb & Sons, Inc. | Method for inhibiting loss of cognitive functions employing an ace inhibitor |
DE3731085A1 (en) * | 1987-09-16 | 1989-04-06 | Hoechst Ag | NEW AMINO ACID ESTERS, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THE USE THEREOF |
DE3739690A1 (en) * | 1987-11-24 | 1989-06-08 | Hoechst Ag | STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS |
DE3801587A1 (en) * | 1988-01-21 | 1989-08-03 | Hoechst Ag | NEW AMINO ACID GLYCERIDES, METHOD FOR THE PRODUCTION THEREOF, MEDICINAL PRODUCTS CONTAINING THEM AND THE USE THEREOF |
EP0331609A3 (en) * | 1988-01-27 | 1992-07-01 | Hoechst Aktiengesellschaft | Angiotensin converting enzyme inhibitors having psychotropic effects |
DE3803225A1 (en) * | 1988-02-04 | 1989-08-17 | Hoechst Ag | AMINO ACID AMIDE WITH PSYCHOTROPIC EFFECT, METHOD FOR THE PRODUCTION THEREOF, AGENTS CONTAINING THE SAME AND THEIR USE |
JPH01275529A (en) * | 1988-03-21 | 1989-11-06 | E R Squibb & Sons Inc | Suppressing treatment agent of delayed motion effect |
US5037821A (en) * | 1988-06-01 | 1991-08-06 | E. R. Squibb & Sons, Inc. | Method for inhibiting loss of cognitive functions employing a calcium channel blocker alone or in combination with an ACE inhibitor |
US5093129A (en) * | 1989-01-30 | 1992-03-03 | E. R. Squibb & Sons, Inc. | Method for treating addiction to a drug of abuse employing an ace inhibitor |
US5032578A (en) * | 1990-09-17 | 1991-07-16 | E. R. Squibb & Sons, Inc. | Method for preventing or treating depression employing a combination of an ace inhibitor and a drug that acts at serotonin receptors |
EP1372620A2 (en) * | 2001-03-15 | 2004-01-02 | Saegis Pharmaceuticals | Methods for restoring cognitive function following systemic stress |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3174844D1 (en) * | 1980-10-23 | 1986-07-24 | Schering Corp | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
DE3300774A1 (en) * | 1983-01-12 | 1984-07-12 | Hoechst Ag, 6230 Frankfurt | NEW SPIROCYCLIC AMINO ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THE USE THEREOF AND NEW SPIROCYCLIC AMINO ACIDS AS INTERMEDIATE PRODUCTS AND METHOD FOR THE PRODUCTION THEREOF |
-
1986
- 1986-03-27 DE DE19863610391 patent/DE3610391A1/en not_active Withdrawn
-
1987
- 1987-03-18 ES ES87103938T patent/ES2061447T3/en not_active Expired - Lifetime
- 1987-03-18 AT AT87103938T patent/ATE102954T1/en not_active IP Right Cessation
- 1987-03-18 EP EP87103938A patent/EP0243645B1/en not_active Expired - Lifetime
- 1987-03-18 DE DE87103938T patent/DE3789330D1/en not_active Expired - Lifetime
- 1987-03-25 HU HU896609A patent/HU202118B/en unknown
- 1987-03-25 EG EG18087A patent/EG18175A/en active
- 1987-03-25 DD DD87301118A patent/DD280765A5/en not_active IP Right Cessation
- 1987-03-25 NZ NZ219764A patent/NZ219764A/en unknown
- 1987-03-25 MA MA21159A patent/MA20919A1/en unknown
- 1987-03-25 HU HU871308A patent/HU203117B/en unknown
- 1987-03-25 FI FI871304A patent/FI91876C/en not_active IP Right Cessation
- 1987-03-25 PH PH35073A patent/PH27210A/en unknown
- 1987-03-26 CA CA000533092A patent/CA1341064C/en not_active Expired - Lifetime
- 1987-03-26 AU AU70649/87A patent/AU621278B2/en not_active Expired
- 1987-03-26 ZA ZA872230A patent/ZA872230B/en unknown
- 1987-03-26 KR KR870002775A patent/KR870008841A/en not_active Application Discontinuation
- 1987-03-26 NO NO871282A patent/NO178546C/en unknown
- 1987-03-26 PT PT84564A patent/PT84564B/en unknown
- 1987-03-26 DK DK153587A patent/DK172221B1/en not_active IP Right Cessation
- 1987-03-26 JP JP62070541A patent/JPS62240698A/en active Pending
- 1987-03-26 IE IE78487A patent/IE62456B1/en not_active IP Right Cessation
- 1987-03-26 RU SU874202302A patent/RU1836335C/en active
- 1987-03-27 CS CS872126A patent/CS212687A3/en unknown
- 1987-03-27 TN TNTNSN87045A patent/TNSN87045A1/en unknown
- 1987-03-27 CS CS896519A patent/CS651989A3/en not_active IP Right Cessation
- 1987-03-27 OA OA59095A patent/OA08506A/en unknown
- 1987-03-27 CN CN87102304A patent/CN1031267C/en not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0096157B1 (en) | Substituted acyl derivatives of 1,2,3,4-tetrahydro-6,7-dimethoxy-3-isoquinolinecarboxylic acid | |
US5120859A (en) | Chimeric amino acid analogues | |
IE870784L (en) | Compounds having a cognition adjuvant action | |
US4483850A (en) | N-Terminal substituted oligopeptide converting enzyme inhibitors | |
EP0219782B1 (en) | Use of angiotensin-converting enzyme inhibitors in the treatment of atherosclerosis, thrombosis and peripheral vascular disease | |
US5231084A (en) | Compounds having a cognition adjuvant action, agents containing them, and the use thereof for the treatment and prophylaxis of cognitive dysfuncitons | |
US5091427A (en) | Piperazinediones having a psychotropic action | |
NO306979B1 (en) | Process for the preparation of a pharmaceutical composition for the treatment of cardiac as well as vascular hypertrophy and hyperplasia | |
US5231080A (en) | Method for the treatment of atherosclerosis, thrombosis, and peripheral vessel disease | |
US5055483A (en) | Novel amino acid glycerides, learning medicaments containing them and their use | |
AU615252B2 (en) | Compounds with a psychotropic action, agents containing them, and the use thereof for the treatment and prophylaxis of disorders of the central nervous system | |
US5114962A (en) | New amino acid esters, a process for their preparation, medicaments containing them, and the use thereof | |
EP0326974A1 (en) | Amino acid amides with a psychotropic activity, processes for their preparation, compositions containing them and their use | |
JPH02200668A (en) | Psychotropic pyrrolidone-2-carboxylic acid derivative | |
GB2050359A (en) | Derivatives of mercaptoacyl amino acids | |
US5043346A (en) | Amino acid esters, pharmaceuticals containing them, and the use thereof in learning disorders | |
KR900003321B1 (en) | Compounds having a cognition adjuvant acton agents containing them,and the use there of the treatment and prophylaxis of cognitives dysfunctions | |
DE3901291A1 (en) | Compounds with psychotropic action, compositions containing these and the use thereof for the treatment and prophylaxis of central nervous system disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK9A | Patent expired |